AREC - Arecor Therapeutics expecting a busy end to the year after solid first half progress
(NewsDirect)
Arecor Therapeutics PLC (AIM:AREC) CEOSarah Howell speaks to Thomas Warner from Proactive after theglobally-focused biopharmaceutical group released its interim resultsfor the six months to 30 June 2023.
Howell gives an overview of recent progress, highlighting theinitiation of the second Phase One clinical study for theirconcentrated rapid-acting insulin, with positive recruitment in type 2diabetes patients.
She alsohighlights fruitful partnerships, such as the one with Hikma, whichobtained FDA confirmation for an accelerated regulatory pathway duringthe reporting period. Arecor's acquisition of Tetris Pharma led tosuccessful commercialisation of their lead product, Ogluo, for severehypoglycemia.
Looking ahead, Arecor anticipates passing somesignificant milestones, including the launch of a biosimilar productand pivotal study progress for a partner's novel medicine. Shesays she's expecting "A busy end to the year and its reallytestament to the great work of Arecor and the team there and also thesupport from our shareholders and investors that we're verygrateful for." Howell attributes the company's achievements toa dedicated team and supportive investors.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.